- Allē Members Enjoy the Aesthetic Treatments They Love Today,
and Pay Over-Time with No Hard Credit Checks
- Participation Comes at No Cost* to Aesthetic Providers for
Allergan Aesthetics Treatments and Products, Increasing
Affordability of Treatments with Flexible Payment Options
IRVINE,
Calif., June 27, 2024 /PRNewswire/
-- Allergan Aesthetics, an AbbVie company (NYSE: ABBV),
today debuted Allē Payment Plans, powered by Cherry. By giving
consumers the power to pay over-time for aesthetic treatments and
products, including BOTOX® Cosmetic (onabotulinumtoxinA)
and the JUVÉDERM® Collection of Fillers, Allē Payment
Plans make aesthetics more accessible and affordable.
Market research shows more than 50 million Americans are
interested in facial injectables, but only a fraction seek
treatment each year, citing cost as the biggest
barrier1. Now, with Allē Payment Plans, patients can pay
for their treatments with a monthly plan making it easier for them
to achieve their aesthetic goals.
"We are excited to debut flexible payment plans within Allē at
no cost* to aesthetic practices for Allergan Aesthetics treatments
and products, increasing the accessibility and affordability
of aesthetic treatments for patients and supporting providers to
welcome new patients," said Jasson Gilmore, Senior Vice
President, U.S. Aesthetics. "Over the last several years, pay
over-time solutions have grown to become a preferred method of
payment for millions of Americans from cell phones to clothing.
Allē Payment Plans help patients pursue the recommended treatments
they want, on terms that work for them."
Allē Payment Plans initial pilot program uncovered key
insights. "We found that 54% of transactions were from patients new
to aesthetics or trying a new service. 34% of transactions included
two or more brands2," shared Jasson Gilmore. "This shows that consumers want
to pay over-time for the recommended aesthetic treatments they have
been considering. Removing cost as a barrier gives them that
opportunity."
The Allē Payment Plans national roll-out begins today, with full
availability across the U.S. expected over the next few months.
"Our practice began accepting Allē Payment Plans as part of a pilot
program. Since then, we've seen an influx of patients who want to
pay over-time and are now interested in learning about additional
treatments to help achieve their aesthetic goals," said Neekan
Rivera, PA, Allergan Medical Institute Trainer and founder of Aère
Aesthetics. "Allē Payment Plans quickly became a seamless part of
our front desk experience, and our patients earn Allē points for
their treatments."
"We are thrilled to partner with Allergan Aesthetics, the market
leader, given their industry defining products and their success
with Allē, the country's leading aesthetics loyalty rewards
platform," said Sean Schroeder, COO
at Cherry. "With Cherry's years of experience in patient financing,
and Allē's leadership in aesthetics rewards, this combined offering
will support practices in helping make aesthetics treatments more
accessible for all."
Allē is offering an inside look of Allē Payment Plans to
providers attending The Aesthetic Show (TAS) in Las Vegas, Nev., June
27-June 30, 2024. Attendees can join a sponsored Lunch and
Learn and can also schedule personalized one-on-one discussions
with an Allergan Digital Consultant at the Allergan Aesthetics
booth to discover how to optimize Allē for Business within their
practice and to prepare for Allē Payment Plans.
In serving more than seven million Members across ~30,000
practices to date, part of Allē's mission is to help educate
consumers about aesthetic treatments, and to simplify office
operations for practices. From its inception, Allē has disrupted
the aesthetics industry by offering the most robust rewards
program. Allē is the first and only loyalty program in the
aesthetics market to also offer consumers the ability to earn
points on over 50 non-Allergan Aesthetics treatments and brands. By
providing Members with information, tools, and incentives, and now
with flexible ways to pay, Allē empowers consumers along their
treatment journey, making the next product purchase or treatment
closer within reach.
To learn more about offering Allē Payment Plans in your
practice, please reach out to your Allergan Aesthetics sales
representative, or
visit http://business.alle.com/payment-plans for more
information.
*Payouts in full are for eligible Allergan Aesthetics products
and treatments only. All other services are subject to standard
Cherry rates.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture,
and market a portfolio of leading aesthetics brands and products.
Our aesthetics portfolio includes facial injectables, body
contouring, plastics, skin care, and more. Our goal is to
consistently provide our customers with innovation, education,
exceptional service, and a commitment to excellence, all with a
personal touch. For more information,
visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
and solutions that solve serious health issues today and address
the medical challenges of tomorrow. We strive to have a remarkable
impact on people's lives across several key therapeutic areas –
immunology, oncology, neuroscience, and eye care – and products and
services in our Allergan Aesthetics portfolio. For more information
about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
LinkedIn, Facebook, Instagram, X (formerly Twitter), and
YouTube.
About Cherry
Cherry's mission is to help medical
providers treat more patients by offering the best payment plan
solution with high approvals, low cost, and a seamless experience.
With leading financing terms for practices and patients, Cherry is
the preferred partner for over 20,000 practices in aesthetics,
dental and beyond. For more information,
visit www.withcherry.com.
BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND
APPROVED USES
Approved Uses
BOTOX® Cosmetic is a
prescription medicine that is injected into muscles and used to
temporarily improve the look of moderate to severe forehead lines,
crow's feet lines, and frown lines between the eyebrows in
adults.
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects
that can be life threatening. Get medical help right away if you
have any of these problems any time (hours to weeks) after
injection of BOTOX® Cosmetic:
- Problems swallowing, speaking, or breathing, due to
weakening of associated muscles, can be severe and result in loss
of life. You are at the highest risk if these problems are
pre-existing before injection. Swallowing problems may last for
several months.
- Spread of toxin effects. The effect of botulinum toxin
may affect areas away from the injection site and cause serious
symptoms including: loss of strength and all-over muscle weakness,
double vision, blurred vision and drooping eyelids, hoarseness or
change or loss of voice, trouble saying words clearly, loss of
bladder control, trouble breathing, and trouble swallowing.
BOTOX® Cosmetic dosing units are not the same as,
or comparable to, any other botulinum toxin product.
There has not been a confirmed serious case of spread of toxin
effect when BOTOX® Cosmetic has been used at the
recommended dose to treat frown lines, crow's feet lines, and/or
forehead lines.
BOTOX® Cosmetic may cause loss of strength or general
muscle weakness, vision problems, or dizziness within hours to
weeks of taking BOTOX® Cosmetic. If this happens, do
not drive a car, operate machinery, or do other dangerous
activities.
Serious and/or immediate allergic reactions have been
reported. They include: itching, rash, red itchy welts,
wheezing, asthma symptoms, or dizziness or feeling faint. Get
medical help right away if you are wheezing or have asthma
symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if
you: are allergic to any of the ingredients in
BOTOX® Cosmetic (see Medication Guide for ingredients);
had an allergic reaction to any other botulinum toxin product such
as Myobloc® (rimabotulinumtoxinB),
Dysport® (abobotulinumtoxinA), or
Xeomin® (incobotulinumtoxinA); have a skin
infection at the planned injection site.
Tell your doctor about all your muscle or nerve
conditions, such as ALS or Lou
Gehrig's disease, myasthenia gravis, or Lambert-Eaton
syndrome, as you may be at increased risk of serious side effects
including difficulty swallowing and difficulty breathing from
typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical
conditions, including: plans to have surgery; had surgery
on your face; have trouble raising your eyebrows; drooping eyelids;
any other abnormal facial change; are pregnant or plan to become
pregnant (it is not known if BOTOX® Cosmetic can harm
your unborn baby); are breast-feeding or plan to (it is not known
if BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you
take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. Using
BOTOX® Cosmetic with certain other medicines may cause
serious side effects. Do not start any new medicines until you
have told your doctor that you have received BOTOX®
Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin
product in the last 4 months; have received injections of botulinum
toxin such as Myobloc®,
Dysport®, or Xeomin® in the
past (tell your doctor exactly which product you received); have
recently received an antibiotic by injection; take muscle
relaxants; take an allergy or cold medicine; take a sleep medicine;
take aspirin-like products or blood thinners.
Other side effects of BOTOX® Cosmetic include:
dry mouth; discomfort or pain at the injection site; tiredness;
headache; neck pain; and eye problems: double vision, blurred
vision, decreased eyesight, drooping eyelids and eyebrows, swelling
of your eyelids and dry eyes.
For more information refer to the Medication Guide or talk with
your doctor.
To report a side effect, please call Allergan at
1-800-678-1605.
Please see BOTOX® Cosmetic full
Product Information including Boxed Warning and
Medication Guide.
JUVÉDERM® Injectable Gel Fillers
Important Information
APPROVED USES
JUVÉDERM® VOLUX® XC injectable gel is for
deep injection to improve moderate to severe loss of jawline
definition in adults over the age of 21.
JUVÉDERM® VOLUMA® XC injectable gel is for
deep injection in the cheek area to correct age-related volume loss
and for augmentation of the chin region to improve the chin profile
in adults over 21.
JUVÉDERM® VOLLURE® XC,
JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra
XC injectable gels are for injection into the facial tissue for the
correction of moderate to severe facial wrinkles and folds, such as
nasolabial folds. JUVÉDERM® VOLLURE® XC
injectable gel is for adults over 21.
JUVÉDERM® Ultra XC injectable gel is also for
injection into the lips and perioral area for lip augmentation in
adults over 21.
JUVÉDERM® VOLBELLA® XC injectable gel is
for injection into the lips for lip augmentation and correction of
perioral lines, and for injection into the undereye hollows to
improve the appearance of undereye hollows in adults over the age
of 21.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive any
JUVÉDERM® formulation?
Do not use these products if you have a history of multiple
severe allergies or severe allergic reactions (anaphylaxis), if you
are allergic to lidocaine or the Gram-positive bacterial proteins
used in these products, or if you have had previous allergic
reactions to hyaluronic acid fillers.
What warnings should my doctor advise me about?
- One of the risks with using dermal fillers is the unintentional
injection into a blood vessel. The chances of this happening are
very small, but if it does happen, the complications can be serious
and may be permanent. These complications, which have been reported
for facial injections, can include vision abnormalities, blindness,
stroke, temporary scabs, or permanent scarring of the skin. Most of
these events are irreversible.
- If you have changes in your vision, signs of a stroke
(including sudden difficulty speaking, numbness or weakness in your
face, arms or legs, difficulty walking, face drooping, severe
headache, dizziness, or confusion), white appearance of the skin,
or unusual pain during or shortly after treatment, you should
notify your health care practitioner immediately.
- The use of dermal fillers where skin sores, pimples, rashes,
hives, cysts, or infections are present should be postponed, as
this may delay healing or make skin problems worse.
- The effectiveness of removal of any dermal filler has not been
studied.
What precautions should my doctor advise me about?
- JUVÉDERM® VOLBELLA® XC should only be
injected into undereye hollows by doctors who have completed the
necessary training for this treatment area. To find a doctor, visit
Juvederm.com/find-a-specialist. Doctors who complete the training
will be listed with a symbol
- The safety of these products for use during pregnancy or while
breastfeeding has not been studied
- The safety of JUVÉDERM® VOLUMA® XC has
not been studied in patients under 35 years or over 65 years for
cheek augmentation, under 22 years or over 80 years for chin
augmentation.
- The safety of JUVÉDERM® VOLUX® XC,
JUVÉDERM® VOLLURE® XC and
JUVÉDERM® VOLBELLA® XC has not been studied
in patients under 22 years, and the safety of JUVÉDERM®
Ultra Plus XC and JUVÉDERM® Ultra XC has not been
studied in patients under 18 years
- The safety and effectiveness of treatment with
JUVÉDERM® products in anatomical regions outside of
their approved uses have not been established in clinical
studies
- If you have a history of excessive scarring (thick, hard scars)
or pigmentation disorders, treatment in these patients has not been
studied and may result in additional scars or changes in
pigmentation
- If you are planning other procedures including laser treatments
or a chemical peel, there is a possible risk of inflammation at the
treatment site if these procedures are performed closely before or
after JUVÉDERM® injectable gel treatment
- Tell your doctor if you are on therapy used to reduce your
body's natural defense system (such as steroids, chemotherapy, and
medicines to treat autoimmune diseases, HIV, and AIDs), as these
may increase your risk of infection; and medications that can
prolong bleeding (such as aspirin, ibuprofen, or other blood
thinners), as these may result in increased bruising or bleeding at
the injection site.
- Avoid applying makeup for 12 hours after treatment and minimize
strenuous exercise, exposure to extensive sun or heat, and
alcoholic beverages within the first 24 hours following treatment,
as these may cause temporary redness, swelling, and/or itching at
the injection site
- JUVÉDERM® VOLUMA® XC was not studied in
patients with significant loose skin of the chin, neck, or jaw
- The effect of JUVÉDERM® VOLUMA® XC
injection into the chin on facial hair growth has not been
studied
- Patients who experience skin injury near the site of
JUVÉDERM® VOLUMA® XC injection may be at a
higher risk for adverse events
- Tell your doctor if you have already been injected with dermal
fillers in the same area as the one(s) you are about to be treated
for. This information helps your doctor decide when and whether you
should get treatment
What are possible side effects of treatment?
The most
commonly reported side effects with JUVÉDERM® injectable
gels were redness, swelling, pain, tenderness, firmness,
lumps/bumps, bruising, discoloration, and itching. For
JUVÉDERM® VOLBELLA® XC, dryness was also
reported.
These side effects are consistent with other facial injection
procedures and most will resolve within 30 days. Your doctor may
choose to treat side effects persisting longer with antibiotics,
steroids, or hyaluronidase (an enzyme that breaks down hyaluronic
acid).
As with all skin injection procedures, there is a risk of
infection.
To report a side effect with any product in the
JUVÉDERM® Collection, please call the
Allergan® Product Support Department at
18773455372. Please also visit Juvederm.com or talk to your doctor
for more information.
Products in the JUVÉDERM® Collection are available
only by a licensed physician or properly licensed practitioner.
References:
- Allergan Aesthetics. Market Research. Data on file. 2024.
- Allergan Aesthetics. Allē Payment Plans Pilot Program Insights.
Data on file. 2024.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/introducing-all-payment-plans-powered-by-cherry-302183902.html
SOURCE AbbVie